Insider · CIK 0001645755

Carvajal Alejandra

Reports to the SEC for 4 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001645755

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-03	CTMXCytomX Therapeutics, Inc.A Award	Chief Legal Officer	AAward	+100K sh	—	—	100,000
2026-08-03	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Legal Officer	AAward	+450K sh	—	—	450,000
2026-01-06	MRSNMersana Therapeutics, Inc.U Disposition from Tender	SVP, Chief Legal Officer	UDisposition from Tender	−3,131 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	SVP, Chief Legal Officer	DDisposition to Issuer	−3,047 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	SVP, Chief Legal Officer	DDisposition to Issuer	−6,702 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	SVP, Chief Legal Officer	DDisposition to Issuer	−4,500 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	SVP, Chief Legal Officer	DDisposition to Issuer	−1,800 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	SVP, Chief Legal Officer	DDisposition to Issuer	−1,527 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	SVP, Chief Legal Officer	DDisposition to Issuer	−4,922 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	SVP, Chief Legal Officer	DDisposition to Issuer	−1,078 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	SVP, Chief Legal Officer	DDisposition to Issuer	−7,921 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitsD Disposition to Issuer	SVP, Chief Legal Officer	DDisposition to Issuer	−100 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitsD Disposition to Issuer	SVP, Chief Legal Officer	DDisposition to Issuer	−717 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitsD Disposition to Issuer	SVP, Chief Legal Officer	DDisposition to Issuer	−1,500 sh	—	—	0
2026-01-06	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitsD Disposition to Issuer	SVP, Chief Legal Officer	DDisposition to Issuer	−2,166 sh	—	—	0
2025-01-16	MRSNMersana Therapeutics, Inc.S Sale	SVP, Chief Legal Officer	SSale	−5,096 sh	$0.58	−$2,955.68	78,296
2025-01-15	MRSNMersana Therapeutics, Inc.S Sale	SVP, Chief Legal Officer	SSale	−952 sh	$0.63	−$599.76	70,892
2025-01-15	MRSNMersana Therapeutics, Inc.M Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	+12.5K sh	—	—	83,392
2025-01-15	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	−12.5K sh	—	—	37,500
2025-01-15	MRSNMersana Therapeutics, Inc. · Stock Option (Right to Buy)A Award	SVP, Chief Legal Officer	AAward	+244K sh	—	—	243,750
2025-01-15	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitA Award	SVP, Chief Legal Officer	AAward	+54.2K sh	—	—	54,167
2025-01-14	MRSNMersana Therapeutics, Inc.M Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	+2,500 sh	—	—	71,844
2025-01-14	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	−2,500 sh	—	—	2,500
2025-01-14	MRSNMersana Therapeutics, Inc.S Sale	SVP, Chief Legal Officer	SSale	−3,330 sh	$0.66	−$2,197.8	69,344
2025-01-13	MRSNMersana Therapeutics, Inc.M Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	+8,958 sh	—	—	72,674
2025-01-13	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	−8,958 sh	—	—	17,917
2024-10-03	MRSNMersana Therapeutics, Inc.S Sale	SVP, Chief Legal Officer	SSale	−5,598 sh	$1.96	−$11K	63,716
2024-10-02	MRSNMersana Therapeutics, Inc.S Sale	SVP, Chief Legal Officer	SSale	−8,089 sh	$2.00	−$16.2K	69,314
2024-10-01	MRSNMersana Therapeutics, Inc.M Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	+50K sh	—	—	77,403
2024-10-01	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	−50K sh	—	—	0
2024-01-16	MRSNMersana Therapeutics, Inc.S Sale	SVP, Chief Legal Officer	SSale	−4,381 sh	$2.71	−$11.9K	27,403
2024-01-15	MRSNMersana Therapeutics, Inc. · Stock Option (Right to Buy)A Award	SVP, Chief Legal Officer	AAward	+225K sh	—	—	225,000
2024-01-15	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitA Award	SVP, Chief Legal Officer	AAward	+50K sh	—	—	50,000
2024-01-14	MRSNMersana Therapeutics, Inc.M Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	+2,500 sh	—	—	31,784
2024-01-14	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	−2,500 sh	—	—	5,000
2024-01-13	MRSNMersana Therapeutics, Inc.M Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	+8,958 sh	—	—	29,284
2024-01-13	MRSNMersana Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	−8,958 sh	—	—	26,875
2023-09-05	MRSNMersana Therapeutics, Inc. · Restricted stock unitA Award	SVP, Chief Legal Officer	AAward	+50K sh	—	—	50,000
2023-04-27	MRSNMersana Therapeutics, Inc.S Sale	SVP, Chief Legal Officer	SSale	−3,944 sh	$3.89	−$15.3K	20,326
2023-04-26	MRSNMersana Therapeutics, Inc.M Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	+13.3K sh	—	—	24,270
2023-04-26	MRSNMersana Therapeutics, Inc. · Restricted stock unitM Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	−13.3K sh	—	—	0
2023-01-17	MRSNMersana Therapeutics, Inc.S Sale	SVP, Chief Legal Officer	SSale	−782 sh	$5.74	−$4,488.68	11,020
2023-01-14	MRSNMersana Therapeutics, Inc.M Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	+2,500 sh	—	—	11,802
2023-01-14	MRSNMersana Therapeutics, Inc. · Restricted stock unitM Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	−2,500 sh	—	—	7,500
2023-01-13	MRSNMersana Therapeutics, Inc. · Stock option (right to buy)A Award	SVP, Chief Legal Officer	AAward	+161K sh	—	—	161,250
2023-01-13	MRSNMersana Therapeutics, Inc. · Restricted stock unitA Award	SVP, Chief Legal Officer	AAward	+35.8K sh	—	—	35,833
2022-04-26	MRSNMersana Therapeutics, Inc.M Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	+13.3K sh	—	—	13,250
2022-04-26	MRSNMersana Therapeutics, Inc.S Sale	SVP, Chief Legal Officer	SSale	−3,948 sh	$3.69	−$14.6K	9,302
2022-04-26	MRSNMersana Therapeutics, Inc. · Restricted stock unitM Exercise/Conversion	SVP, Chief Legal Officer	MExercise/Conversion	−13.3K sh	—	—	13,250
2022-01-14	MRSNMersana Therapeutics, Inc. · Stock Option (right to buy)A Award	SVP, Chief Legal Officer	AAward	+45K sh	—	—	45,000

Recent filings

Accepted (ET)
Aug 54
Carvajal Alejandra0001610717-26-000351
SEC(opens sec.gov)
Jan 64
Carvajal Alejandra0001104659-26-001380
SEC(opens sec.gov)
Jan 174
Carvajal Alejandra0001104659-25-004591
SEC(opens sec.gov)

Companies

Address

C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., STE. 400

SOUTH SAN FRANCISCO, CA, 94080